Sign in Subscribe
Cancer research

Yunnan Cancer Hospital Conducts Clinical Trial to Study Metformin's Effectiveness in Advanced Lung Squamous Cell Carcinoma

Strategic Insights

— 1 min read

Yunnan Cancer Hospital has registered a clinical trial to investigate the efficacy of metformin hydrochloride extended release tablets in combination with immune checkpoint inhibitors to treat advanced or metastatic lung squamous cell carcinoma. The study aims to enroll 70 participants with locally advanced or metastatic squamous non-small cell lung cancer who have not received systematic treatment and will be randomly divided into two groups. The experimental group will receive immune checkpoint inhibitors and metformin hydrochloride extended release tablets, while the control group will receive immune checkpoint inhibitors and placebos. The study will assess the progression-free survival time, overall survival, duration of response, and safety of treatment.

Key Takeaways:

  • The clinical trial aims to enroll 70 participants with locally advanced or metastatic squamous non-small cell lung cancer.
  • The study will randomly divide participants into two groups: one receiving immune checkpoint inhibitors and metformin hydrochloride extended release tablets, and the other receiving immune checkpoint inhibitors and placebos.
  • The study will assess the efficacy and safety of metformin hydrochloride extended release tablets in combination with immune checkpoint inhibitors.
  • The primary study endpoints include progression-free survival time, and secondary study endpoints include overall survival, duration of response, and safety of treatment.
  • The study is an investigator-initiated study, meaning it was initiated by researchers at Yunnan Cancer Hospital.

Statistics:

  • The study aims to enroll 70 participants.
  • The study will be conducted at multiple centers and will be a randomized, controlled, double-blind trial.
  • The clinical trial registration number is ChiCTR2500107128.
  • The study will assess the efficacy and safety of metformin hydrochloride extended release tablets in combination with immune checkpoint inhibitors.

Sources:

  • Chinese Clinical Trial Registry ( date not specified )

https://www.chictr.org.cn/

  • Contify.com ( copyright 2017 )

https://contify.com/

Read more